Back

Compassionate Use of Tocilizumab in Severe SARS-CoV2 Pneumonia. When late administration is too late.

2020-06-16 infectious diseases Title + abstract only
View on medRxiv
Show abstract

IntroductionTocilizumab is an interleukin 6 receptor antagonist which has been used for the treatment of severe SARS-CoV-2 pneumonia (SSP), aiming to ameliorate the cytokine release syndrome (CRS) -induced acute respiratory distress syndrome (ARDS). However, there is no data about the best moment for its administration along the course of the disease. MethodsWe provided tocilizumab on a compassionate-use basis to patients with SSP hospitalized (excluding intensive care and intubated cases) who ...

Predicted journal destinations

1
PLOS ONE
1737 training papers
Top 64% 8.4%
2
Clinical Infectious Diseases
219 training papers
Top 5% 6.0%
3
Scientific Reports
701 training papers
Top 52% 5.5%
4
Open Forum Infectious Diseases
124 training papers
Top 1% 5.5%
5
Frontiers in Medicine
99 training papers
Top 2% 4.7%
6
International Journal of Infectious Diseases
115 training papers
Top 2% 4.7%
7
Clinical Microbiology and Infection
54 training papers
Top 1.0% 2.6%
8
BMJ Open
553 training papers
Top 44% 2.6%
9
The Journal of Infectious Diseases
137 training papers
Top 6% 2.0%
10
Journal of Clinical Virology
54 training papers
Top 2% 2.0%
11
BMC Infectious Diseases
110 training papers
Top 5% 2.0%
12
New England Journal of Medicine
49 training papers
Top 1% 1.8%
13
Vaccines
131 training papers
Top 5% 1.8%
14
eClinicalMedicine
55 training papers
Top 0.6% 1.8%
15
Journal of Infection
64 training papers
Top 2% 1.8%
16
Nature Medicine
88 training papers
Top 4% 1.8%
17
Journal of Medical Virology
95 training papers
Top 6% 1.8%
18
Journal of Clinical Medicine
77 training papers
Top 10% 1.8%
19
Frontiers in Immunology
140 training papers
Top 7% 1.8%
20
Infectious Diseases and Therapy
18 training papers
#1 1.8%
21
Nature Communications
483 training papers
Top 41% 1.8%
22
JAMA Network Open
125 training papers
Top 15% 1.4%
23
European Respiratory Journal
44 training papers
Top 3% 1.2%
24
Vaccine
140 training papers
Top 7% 1.1%
25
BMJ
49 training papers
Top 4% 1.1%
26
JCI Insight
63 training papers
Top 6% 1.1%
27
The Lancet Infectious Diseases
57 training papers
Top 6% 1.1%
28
Clinical Pharmacology & Therapeutics
19 training papers
Top 1% 0.9%
29
Viruses
79 training papers
Top 12% 0.7%
30
Eurosurveillance
77 training papers
Top 16% 0.7%